# Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

> **NCT07164469** · PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 100 (estimated)

## Conditions studied

- Large B-cell Lymphoma
- Hodgkin Lymphoma

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** CD70.CAR NK Cells
- **DRUG:** Rimiducid (AP1903)

## Key facts

- **NCT ID:** NCT07164469
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-28
- **Primary completion:** 2031-09-30
- **Final completion:** 2033-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07164469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07164469, "Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07164469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*